Check-Cap Stock (NASDAQ:CHEK)
Previous Close
$0.82
52W Range
$0.76 - $3.62
50D Avg
$1.39
200D Avg
$1.95
Market Cap
$4.53M
Avg Vol (3M)
$17.41K
Beta
0.18
Div Yield
-
CHEK Company Profile
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.
CHEK Performance
Peer Comparison
| Ticker | Company |
|---|---|
| GTH | Genetron Holdings Limited |
| LMDX | LumiraDx Limited |
| SERA | Sera Prognostics, Inc. |
| BNR | Burning Rock Biotech Limited |
| PMD | Psychemedics Corporation |
| PRE | Prenetics Global Limited |
| CSTL | Castle Biosciences, Inc. |
| ACRS | Aclaris Therapeutics, Inc. |
| NOTV | Inotiv, Inc. |
| DRIO | DarioHealth Corp. |
| OLK | Olink Holding AB (publ) |
| BDSX | Biodesix, Inc. |
| FONR | FONAR Corporation |
| STIM | Neuronetics, Inc. |
| MDXH | MDxHealth SA |